GlassScriptPhysician profile
Sarah Saeed
NPI 1639606411
$4,659.68
in general payments reported to CMS, 2019-2025
25 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.82 · 2021: $170 · 2023: $673 · 2024: $2,073 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.94 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $858.86 | 2023-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $643.80 | 2021-2025 | Skyrizi |
| Amgen INC. | $536.30 | 2023-2025 | Krystexxa, Evenity, Prolia |
| Ucb, INC. | $377.72 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $355.48 | 2023-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $312.51 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $294.44 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $229.28 | 2023-2025 | Acthar |
| Lilly USA, LLC | $210.29 | 2023-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.16 | 2021-2024 | Cyltezo, Ofev |
| Astrazeneca Pharmaceuticals LP | $121.86 | 2024-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $103.51 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $86.97 | 2024 | Strensiq, Ultomiris |
| Octapharma USA, INC. | $77.89 | 2025 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $62.06 | 2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $42.12 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $31.17 | 2024 | Orencia |
| Fresenius Kabi USA, LLC | $29.69 | 2024 | Idacio |
| Teva Pharmaceuticals USA, INC. | $20.67 | 2025 | Simlandi |
| Sobi, INC | $20.05 | 2024 | |
| Sandoz INC. | $18.30 | 2023 | Hyrimoz |
| Galderma Laboratories, L.P. | $16.85 | 2025 | |
| Pfizer INC. | $16.82 | 2020 | |
| Depuy Synthes Sales INC. | $16.80 | 2024 | Monovisc |
| Genentech USA, INC. | $16.08 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.